BDR Pharma launches India's first generic cancer treatment drug Midostaurin
BDR Pharma has launched the country's first generic Midostaurin under the brand name MSTARIN to treat cancer.;
New Delhi: BDR Pharma on Monday said it has launched a generic cancer treatment drug in the country.
The company has launched the country's first generic Midostaurin under the brand name MSTARIN, which is indicated in rare, hard-to-treat cancers, BDR Pharma said in a statement.
The drug is approved for use in combination with standard Daunorubicin and Cytarabine induction and high-dose Cytarabine consolidation chemotherapy, and for patients with newly diagnosed Acute Myeloid Leukemia (AML) who are FLT3 mutation-positive.
AML (Acute Myeloid Leukemia) is the most common leukemia or blood cancer in adults.
It accounts for around 25 percent of all adult Leukemia worldwide, with the highest incidence rates and also the lowest survival rates of all adult leukemia.
''With the launch of the generic Midostaurin, patients with FLT3 mutated AML will now have access to this medicine at an affordable cost that could significantly extend their lives,'' BDR Pharmaceuticals Director – Business Development Raheel Shah was quoted as saying by PTI.
The Mumbai-based BDR Pharma focuses on development in specialized therapeutic segments, like oncology, critical care, gynaecology, neurology, dermatology and women's health.
Read also: BDR Pharma unveils generic cancer drug Cabozantinib in India
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.